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Influenza pandemic (H1N1) 2009 worldwide
The novel influenza (H1N1) 2009 virus continues to spread at an unprecedented speed with many countries now showing sustained community
transmission. TheWHO stopped issuing global tables of figures for confirmed cases on 6 July 2009. Data from the ECDCwebsite showed the total
number of confirmed and reported cases globally to be 154,985 with 917 deaths as of 17:00 h CEST (GMT + 2) 24 Jul 2009 (http://
ecdc.europa.eu/en/files/pdf/Health_topics/Situation_Report_090724_1700hrs.pdf). Out of the 31 EU and EFTA countries, 30 have reported
a total of 20,382 cases, including 35 deaths. Several countries, including the United Kingdom, have now moved to a treatment phase based on
clinical symptoms and signs only, with targeted laboratory testing only for specific population groups or outbreaks.
The majority of cases are characterised by mild flu-like symptoms and complete recovery within a week of onset of symptoms, even in the
absence of medical treatment. However, severe complications including rapidly progressive lower respiratory tract disease leading to
respiratory failure, development of acute respiratory distress syndrome (ARDS) and prolonged intensive care admission have been reported. A
recent report on a series of 10 patients with novel influenza A (H1N1) infection admitted to a Michigan intensive care unit with ARDS has
highlighted the potential for severe complications, particularly in extremely obese patients (http://www.cdc.gov/mmwr/preview/
mmwrhtml/mm58d0710a1.htm). A 26-year old woman admitted to her local hospital in Kilmarnock, Scotland critically ill with the virus
had to be transferred to Stockholm, Sweden for extra-corporeal membrane oxygenation (ECMO). Severe illness among pregnant women and
infants has also been reported with the current pandemic. Rare complications are also emerging; four children were admitted to hospitals in
Dallas County between 18-28 May 2009 with neurological complications characterized by seizures and altered mental status (ProMed Mail
archive number 20090723.2606). Novel influenza A (H1N1) viral RNA was detected in nasopharyngeal specimens but not cerebrospinal fluid. All
4 children recovered completely with no neurological sequelae at discharge.
Seasonal influenza (H3N2) virus — vaccine mismatch
A new emerging strain of H3N2 virus circulating in some parts of the southern hemisphere has been reported to show reduced response to
antibodies generated by the corresponding virus in the seasonal vaccine (ProMED Mail archive number 20090724.2623). This new variant was
spotted in early March 2009 by a group of researchers at the British Columbia Centre for Disease Control and first reported by ProMED mail on 5
May 2009 (ProMed Mail archive number 20090505.1679). Although at present this variant remains a minority member of the H3N2 strains, a
change in dominance could potentially lead to the spectre of a vaccine mismatch. Spread of this variant as the predominant seasonal influenza
strain could also pose a problem particularly for patient groups such as the elderly that hitherto have remained less affected by the ongoing
novel influenza (H1N1) pandemic.
Trypanosomiasis — Netherlands ex Tanzania
A 25-year old woman presented to a hospital in the Netherlands with fever, headache and a large blister on her left forearm (ProMED Mail
archive number 20090724.2613). She had returned the same day from a holiday to Tanzania and had been bitten by grey flies 8 days earlier
during a visit to Serengetti Park. Blood film examination showed trypomastigotes but cerebrospinal fluid examination was normal. A diagnosis
of stage I human African trypanosomiasis by Trypanosoma brucei rhodesiense was made, and the patient was commenced on treatment with
suramin.
Trypanosoma brucei rhodesiense, a flagellated protozoan parasite, is the etiologic agent of east African trypanosomiasis. The disease is
endemic in central Africa and has been emerging in the Congo DR over the past 15—20 years. The parasite is transmitted by tsetse flies of the
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morsitans group that are widely distributed throughout the savannah areas of central and east Africa. Wild animals such as antelopes are the
main reservoir but cattle have also served as reservoirs of infection. The clinical course of the disease is characterised by intermittent bouts of
high temperature, malaise and rash due to dissemination of the parasite (stage 1), progressing to meningoencephalitis (stage II); death ensues
within weeks to months if the patient is left untreated. An indurated painful chancre may appear at the site of inoculation, but most patients
may progress to disseminated disease without having local symptoms.
The last reported case in a visitor to Serengeti Park occurred in June 2009 in an American tourist who presented with multi-organ failure but
recovered fully following treatment with suramin. Ten cases of trypanosomiasis in tourists visiting Serengeti and Tarangire national parks were
reported in 2001 and a further 2 cases in 2005.
Pneumonic plague in China
Source: Xinhua News Agency [edited]. http://news.xinhuanet.com/english/2009-08/05/content_11831481.htm
As of late Tuesday, 4 Aug 2009 [ProMED-mail archive number 20090805.2764] a total of 12 cases of pneumonic plague have been confirmed in
Xinghai County in the Hainan Tibetan Autonomous Prefecture of northwest China’s Qinghai Province. Pneumonic plague, like bubonic plague is
caused by Yersinia pestis, a Gram-negative bacillus that is spread from rodents to people via fleas. In pneumonic plague, cases can be
transmitted directly from person-to-person without a flea vector and is associated with a high mortality rate. The reported cases include 3
deaths, 1 near death, and 1 patient who is in serious condition. The others are stable.
Local government has sealed off and quarantined the town of Ziketan, the source of the outbreak and provincial health authorities have
deployed a team of experts to the area. There has been no report of new infections.
At present, 218 people are quarantined in the hospital, and 115 of them had been in close contact with those infected. Local authorities have
handed out more than 40,000 leaflets and disks on plague prevention.
According to ProMED-mail moderator Larry Lutwick, ‘‘It is now clearly stated that pneumonic plague has occurred in all 12 individuals, 11 of
whomwere exposed to the index case. It is not stated how soon antimicrobial therapy was begun in the affected persons. It is generally said (1)
that treatment of primary plague pneumonia (primary here means acquired via the respiratory route) should be begun once of the diagnosis is
suspected since a delay of more than 18 hours produces a very high mortality rate. It is also not stated whether antimicrobial prophylaxis is
being used in the 115 individuals who had been in close contact with the cases.’’
New Strain of HIV in a human: gorilla origin
Gorillas have been found, for the first time, to be a source of human HIV [human immunodeficiency virus]. The summary of the scientific article
that has been extensively quoted in the mainstream media is:
We have identified a new human immunodeficiency virus in a Cameroonian woman. It is closely related to gorilla simian immunodeficiency virus
(SIVgor) and shows no evidence of recombination with other HIV-1 lineages. This new virus seems to be the prototype of a new HIV-1 lineage
that is distinct from HIV-1 groups M, N and O. We propose to designate it HIV-1 group P.
The title of the article is ‘‘A new human immunodeficiency virus derived from gorillas.’’ By Jean-Christophe Plantier, Marie Leoz, Jonathan E
Dickerson, Fabienne De Oliveira, Francois Cordonnier, Veronique Lemee, Florence Damond, David L Robertson and Francois Simon. Nature
Medicine, Published online: 02 August 2009. DOI:10.1038/nm.2016 http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.2016.html
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